Cargando…
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317999/ https://www.ncbi.nlm.nih.gov/pubmed/37400508 http://dx.doi.org/10.1038/s41408-023-00870-2 |
| _version_ | 1785067941461491712 |
|---|---|
| author | Hengeveld, P. J. Schilperoord-Vermeulen, J. van der Klift, M. Y. Dubois, J. M. N. Kolijn, P. M. Kavelaars, F. G. Rijken, M. Dobber, J. A. Nasserinejad, K. Kersting, S. Westerweel, P. E. Kater, A. P. Langerak, A. W. Levin, M-D. |
| author_facet | Hengeveld, P. J. Schilperoord-Vermeulen, J. van der Klift, M. Y. Dubois, J. M. N. Kolijn, P. M. Kavelaars, F. G. Rijken, M. Dobber, J. A. Nasserinejad, K. Kersting, S. Westerweel, P. E. Kater, A. P. Langerak, A. W. Levin, M-D. |
| author_sort | Hengeveld, P. J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10317999 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103179992023-07-05 Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia Hengeveld, P. J. Schilperoord-Vermeulen, J. van der Klift, M. Y. Dubois, J. M. N. Kolijn, P. M. Kavelaars, F. G. Rijken, M. Dobber, J. A. Nasserinejad, K. Kersting, S. Westerweel, P. E. Kater, A. P. Langerak, A. W. Levin, M-D. Blood Cancer J Correspondence Nature Publishing Group UK 2023-07-04 /pmc/articles/PMC10317999/ /pubmed/37400508 http://dx.doi.org/10.1038/s41408-023-00870-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Hengeveld, P. J. Schilperoord-Vermeulen, J. van der Klift, M. Y. Dubois, J. M. N. Kolijn, P. M. Kavelaars, F. G. Rijken, M. Dobber, J. A. Nasserinejad, K. Kersting, S. Westerweel, P. E. Kater, A. P. Langerak, A. W. Levin, M-D. Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia |
| title | Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia |
| title_full | Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia |
| title_fullStr | Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia |
| title_full_unstemmed | Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia |
| title_short | Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia |
| title_sort | early-stage measurable residual disease dynamics and ighv repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317999/ https://www.ncbi.nlm.nih.gov/pubmed/37400508 http://dx.doi.org/10.1038/s41408-023-00870-2 |
| work_keys_str_mv | AT hengeveldpj earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT schilperoordvermeulenj earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT vanderkliftmy earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT duboisjmn earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT kolijnpm earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT kavelaarsfg earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT rijkenm earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT dobberja earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT nasserinejadk earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT kerstings earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT westerweelpe earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT katerap earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT langerakaw earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia AT levinmd earlystagemeasurableresidualdiseasedynamicsandighvrepertoirereconstitutionduringvenetoclaxandobinutuzumabtreatmentinchroniclymphocyticleukemia |